GlaxoSmithKline

GSK's Menveo, a fully liquid MenACWY vaccine, received EC approval for active immunisation from age 2, simplifying administration. The vaccine aims to protect against invasive meningococcal disease caused by serogroups A, C, W, and Y. GSK's commitment to innovation in meningococcal vaccines supports vaccine uptake and prevention efforts in the EU.

EC approves GSK's fully liquid Menveo vaccine for invasive meningococcal disease (IMD) in children, adolescents, and adults, based on Phase IIb trials showing comparable immunogenicity and safety to current formulations.

Pharmaceutical companies conduct most clinical trials in countries where they plan to market products, often neglecting low and middle-income countries (LMICs), particularly in sub-Saharan Africa. This exclusion limits access to life-saving treatments and therapies for patients in these regions. The Access to Medicine Foundation report highlights a gap in product registration in Africa, with 43% of innovative products approved in the past five years not registered in any African countries. The report calls for pharmaceutical companies to prioritize equitable access and work with local partners to build research capabilities in LMICs.

The US FDA accepted GSK's BLA for belantamab mafodotin (Blenrep) in combinations with bortezomib plus dexamethasone and pomalidomide plus dexamethasone for treating multiple myeloma patients who have received at least one previous therapy. The decision is based on positive results from Phase III clinical trials DREAMM-7 and DREAMM-8, which showed significant improvements in progression-free survival. Belantamab mafodotin is an antibody-drug conjugate already under review in the EU, Japan, UK, Canada, and Switzerland.

Six companies—Ionis Pharmaceuticals, Isarna Therapeutics, Regulus Therapeutics, Sarepta Therapeutics, Secarna Pharmaceuticals, and Wave Life Sciences—are leading in the development of antisense oligonucleotides, a targeted treatment for various diseases. Ionis, a pioneer with over 40 drugs in its pipeline, recently priced a $500 million IPO. Isarna's ISTH0036 targets TGF-β for ophthalmic conditions. Regulus focuses on microRNA targeting with its lead candidate RGLS8429 for ADPKD. Sarepta has three approved PPMO therapies for DMD and a recent $1 billion deal with Arrowhead Pharmaceuticals. Secarna's SECN-15 targets NRP1 for oncology. Wave Life Sciences' WVE-003, for Huntington's disease, recently reported positive phase 1b/2a trial results. The antisense oligonucleotide market is projected to grow to $5,519 million by 2033.

EC approves GSK’s fully liquid Menveo vaccine for IMD prevention in children, adolescents, and adults, simplifying vaccination process.

GSK's fully liquid Menveo meningococcal vaccine approved by European Commission, simplifying vaccination process against invasive meningococcal disease.

Linerixibat, an oral medication by GSK, significantly reduced itching in PBC patients in a Phase 3 trial, meeting its main goal. The drug, targeting IBAT to ease itching, could be the first global therapy for PBC-related itch. GSK predicts over 240,000 PBC patients worldwide will need treatment for relentless itch by 2030. The trial, facilitated by Science 37, allowed remote participation, nearly doubling U.S. enrollment.

GSK’s linerixibat showed significant reduction in itch scores in a phase 3 trial for PBC patients, meeting its primary endpoint and potentially addressing a root cause of cholestatic pruritus.